Literature DB >> 3769388

Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer.

K D Haegele, P J Schechter.   

Abstract

Six healthy men received single oral doses of 1500 mg of vigabatrin [(R,S)-gamma-vinyl-GABA] and 750 mg of S(+)-gamma-vinyl-GABA on two occasions. Concentrations of the individual enantiomers were assayed by a stereoselective procedure based on combined GC/MS. At peak, concentrations of the R(-)-enantiomer exceeded concentrations of the S(+)-enantiomer, with an approximate ratio of 2:1. The mean terminal t1/2 ranged from 6 to 8 hours for both enantiomers. Mean urinary recovery of the S(+)-enantiomer was 49% after both doses and was 65% for the R(-)-enantiomer. Plasma concentration values obtained for the S(+)-enantiomer after a dose of the pure S(+)-enantiomer and an equivalent dose of the racemate showed good agreement for both the concentrations observed at any time point and the elimination characteristics, demonstrating bioequivalence. Renal clearance values for the S(+)-enantiomer are not affected by concomitant dosing with the pharmacologically inactive R(-)-enantiomer. No chiral inversion was detected after dosing with the pure S(+)-enantiomer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769388     DOI: 10.1038/clpt.1986.227

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

1.  Passage of S(+) and R(-) gamma-vinyl-GABA across the human isolated perfused placenta.

Authors:  J C Challier; E Rey; T Bintein; G Olive
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Effect of food on the absorption of vigabatrin.

Authors:  M Frisk-Holmberg; P Kerth; P Meyer
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers.

Authors:  A Tran; T O'Mahoney; E Rey; J Mai; J P Mumford; G Olive
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

4.  Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.

Authors:  Juseop Kang; Yoo-Sin Park; Shin-Hee Kim; Sang-Hyun Kim; Min-Young Jun
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

5.  Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children.

Authors:  E Rey; G Pons; M O Richard; F Vauzelle; P D'Athis; C Chiron; O Dulac; D Beaumont; G Olive
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 6.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 7.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 8.  Clinical pharmacology of vigabatrin.

Authors:  P J Schechter
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 9.  Clinical management of seizures in newborns : diagnosis and treatment.

Authors:  Linda G M van Rooij; Marcel P H van den Broek; Carin M A Rademaker; Linda S de Vries
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 10.  Vigabatrin. Clinical pharmacokinetics.

Authors:  E Rey; G Pons; G Olive
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.